{"product_id":"organogenesis-pestle-analysis","title":"Organogenesis PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic edge with our PESTLE Analysis of Organogenesis—uncover how political, economic, social, technological, legal, and environmental forces are shaping its trajectory and risks. Perfect for investors, consultants, and strategists, this concise yet powerful report delivers actionable insights to inform decisions and forecasts. Purchase the full version for the complete, editable analysis and start applying data-driven intelligence today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMS Reimbursement Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CMS shift toward standardized outpatient wound-care bundles by end-2025 ties reimbursement for skin substitutes to bundled payments covering visits, dressings and products, with CMS projecting 5–8% annual savings versus fee-for-service in pilot regions.\u003c\/p\u003e\n\u003cp\u003eThese bundles reduce average reimbursement per episode from roughly $3,200 to an estimated $2,900, pressuring adoption of Organogenesis’s higher-cost living cell products (often 30–150% pricier than acellular options).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Election Healthcare Reform Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the 2024 elections, 2025 US policy debates emphasize cutting healthcare spending and lowering drug prices; congressional proposals target $100B+ in annual pharma savings and Medicare negotiation expansion affecting reimbursement for advanced wound care. Possible ACA tweaks or Medicare expansion could shift payer mix—Medicare\/Medicaid now cover ~40% of wound-care patients—pressuring margins. Management must pivot toward value-based outcomes as CMS ties 30%+ payments to value models by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Regulatory Pathway Evolution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe FDA has tightened HCT\/P classifications, increasing Biologics License Application scrutiny; by 2024 the agency completed over 120 enforcement actions affecting cell\/tissue firms. Organogenesis faces political pressure to convert select legacy products to BLA pathways by late 2025, risking revenue disruption—these SKUs represented roughly 18% of 2023 revenue. Meeting new requirements demands substantial regulatory spend and stakeholder engagement to preserve market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Geopolitical Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas organogenesis expands globally us trade policies and tariffs averaging on medical goods affect export pricing margins in key markets like eu china.\u003e\n\u003cpgeopolitical tensions in including supply-chain disruptions tied to regional conflicts heighten risks for exporting sensitive biologics and partnerships with of biotech firms reporting delayed shipments\u003e\n\u003cppolitical stability in sourcing regions latin america india is vital disruptions can delay trials and impact revenue growth reported exposure to international markets fy2024.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS tariffs ~3.5% on medical goods (2024)\u003c\/li\u003e\n\u003cli\u003e12% of biotech firms faced shipment delays (2024)\u003c\/li\u003e\n\u003cli\u003e8% of Organogenesis FY2024 revenue exposure to international markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppolitical\u003e\u003c\/pgeopolitical\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding for Biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal grants and subsidies for regenerative medicine sustain Organogenesis's R\u0026amp;D pipeline; NIH funding rose to $47.5B in FY2024, and a 2.5% cut proposed in 2025 would tighten early-stage translational work funding.\u003c\/p\u003e\n\u003cp\u003eChanges in congressional allocations to NIH, BARDA, or Cures Act programs directly affect supplier networks and clinical partnerships critical to Organogenesis's product development.\u003c\/p\u003e\n\u003cp\u003eA favorable political push for domestic biotech manufacturing, backed by Inflation Reduction Act and CHIPS-style incentives, is key for Organogenesis to retain cost and supply advantages versus lower-cost international rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH budget FY2024: $47.5B; FY2025 proposed cut ~2.5%\u003c\/li\u003e\n\u003cli\u003eFederal manufacturing incentives growing under IRA\/CHIPS-style programs\u003c\/li\u003e\n\u003cli\u003eDependence on sustained grant flow for translational\/regenerative projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement \u0026amp; regulation squeeze Organogenesis: CMS cuts, FDA scrutiny vs NIH\/IRA relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts (CMS bundles, Medicare negotiation, FDA BLA scrutiny) pressure Organogenesis’s reimbursement, pricing and regulatory costs; CMS value models (30%+ by 2026) and bundle cuts (~$300\/episode) compress margins while NIH funding ($47.5B FY2024; proposed −2.5% FY2025) and IRA manufacturing incentives partially offset R\u0026amp;D and domestic production risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\/Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS bundles\u003c\/td\u003e\n\u003ctd\u003e−$300\/episode; 5–8% pilot savings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share\u003c\/td\u003e\n\u003ctd\u003e~40% patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA enforcement\u003c\/td\u003e\n\u003ctd\u003e120+ actions (by 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH\u003c\/td\u003e\n\u003ctd\u003e$47.5B FY2024 (−2.5% proposed)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely affect Organogenesis across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and region-specific insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Organogenesis's PESTLE insights into a concise, shareable summary that highlights regulatory, market, and technological risks—ideal for quick reference in meetings, presentations, or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Payer Constraints and Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025 commercial insurers and government payers increased reimbursement scrutiny, with Medicare cutting advanced wound-care add-on payments by ~8% and private payers accelerating prior authorizations; Organogenesis must prove superior outcomes to sustain premium pricing for its living-cell portfolio.\u003c\/p\u003e\n\u003cp\u003eStudies show 12-month healing rates and reduced readmissions drive coverage decisions—Organogenesis needs robust real-world evidence as hospitals shift to capitated models where upfront costs of regenerative tech are evaluated against per-patient cost targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of Capital for Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite a stabilizing interest rate environment in late 2025, borrowing costs for clinical-stage biotech remain elevated—average yields on BBB US corporate debt hovered near 5.5% and term loan spreads for healthcare deals averaged ~420 bp—keeping large-scale trial financing expensive for Organogenesis.\u003c\/p\u003e\n\u003cp\u003eOrganogenesis must balance existing debt (net leverage ~1.8x as of FY2024) against reinvestment needs in surgical and sports medicine pipelines, where phase II\/III programs can cost $50–200M each.\u003c\/p\u003e\n\u003cp\u003eEconomic volatility reduced favorable equity windows in 2024–25, with biotech IPO activity down ~35% year-over-year, increasing reliance on internal cash flow and partnerships to fund expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppersistent inflation has driven labor costs up about annually through raising wages for skilled lab technicians central to organogenesis biologics production. the price of specialized medical supplies and cold-chain logistics living tissue transport rose roughly year-over-year lifting baseline operating expenses. these input cost increases threaten compress gross margins unless executive team implements pricing efficiency or sourcing strategies in\u003e\n\u003c\/ppersistent\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Expansion Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFluctuations in FX rates (USD vs EUR\/GBP\/JPY) can swing Organogenesis margins by 2–5% on exported product revenue as global sales scale; FY2024 international revenue share reached roughly 28% of total, heightening exposure.\u003c\/p\u003e\n\u003cp\u003eEconomic instability in key emerging markets (LMIC healthcare spend growth slowed to ~3% in 2024) could constrain procurement of high-end regenerative therapies, limiting near-term addressable markets.\u003c\/p\u003e\n\u003cp\u003eThe company should deploy dynamic hedging—forwards, options, natural hedges—to shield revenue; targeted hedging reduced FX losses by an estimated 1.2% in comparable medical-device peers in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~28% international revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eFX-driven margin variability ~2–5%\u003c\/li\u003e\n\u003cli\u003eEmerging-market healthcare spend growth ~3% (2024)\u003c\/li\u003e\n\u003cli\u003eHedging can recapture ~1.2% lost to FX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Disposable Income Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDeclining disposable income reduces elective surgical volumes; US personal saving rate fell to 3.6% in 2024 while real disposable income declined 0.4% YoY in Q3 2024, prompting deferment of non-essential soft-tissue reconstructions and orthopedic procedures that drive Organogenesis surgical product demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElective procedures sensitive to consumer income\u003c\/li\u003e\n\u003cli\u003eReal disposable income -0.4% YoY Q3 2024 (US)\u003c\/li\u003e\n\u003cli\u003eSaving rate 3.6% in 2024\u003c\/li\u003e\n\u003cli\u003eLower procedural volume → reduced product demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs, FX risk and reimbursement pressure squeeze medtech margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising reimbursement scrutiny and need for real-world evidence; elevated borrowing costs (BBB yields ~5.5%, loan spreads ~420 bp) raise trial finance costs; input inflation up 10–12% for supplies and 6–8% labor increases compress margins; FX swings (2–5% margin impact) with ~28% international revenue; elective procedure demand hit by real disposable income -0.4% YoY (Q3 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e~28% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBBB yield\u003c\/td\u003e\n\u003ctd\u003e~5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoan spreads\u003c\/td\u003e\n\u003ctd\u003e~420 bp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply inflation\u003c\/td\u003e\n\u003ctd\u003e10–12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor inflation\u003c\/td\u003e\n\u003ctd\u003e6–8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX margin swing\u003c\/td\u003e\n\u003ctd\u003e2–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal DPI\u003c\/td\u003e\n\u003ctd\u003e-0.4% YoY Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eOrganogenesis PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Organogenesis PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751203090809,"sku":"organogenesis-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organogenesis-pestle-analysis.png?v=1772228839","url":"https:\/\/matrixbcg.com\/products\/organogenesis-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}